News

“While the economic and capital markets outlook for 2009 remains uncertain, the regenerative medicine and stem cell sectors have gained significant momentum and exposure since the beginning of

Ablynx, a developer of antibody-derived therapeutic proteins, has announced that it will receive milestone payments totaling E3m from Boehringer Ingelheim triggered as part of its strategic alliance for

This decision follows a successful end-of-Phase II meeting with the FDA, held on January 30, 2009. Algeta began enrolling patients for its global Phase III Alsympca study in

As previously reported, 29 of 109 evaluable patients, or 27%, achieved a response as assessed by central independent oncology review, which is the primary endpoint of the trial.

The objective of the first part of the program was to acquire the set of Altropane images which will be used to train expert readers for the Phase

For the past five months, Mr Cuesta has been overseeing the region in an acting capacity. Mr Cuesta joined the company in August 2005 as country director for

Christopher Menard, currently Phase Forward’s vice president of finance, will succeed Weismann as CFO at that time. After June 1, 2009 Weismann will serve in a part-time capacity

BioMarin Pharmaceutical has announced results from its Phase II multi-center, randomized, double-blind, placebo-controlled clinical study of 6R-BH4 in patients with symptomatic peripheral arterial disease. There was no statistical

This technology is based on the findings of a study led by Jean-Claude Tardif at the Montreal Heart Institute research center in Canada. In Dr Tardif’s placebo-controlled study